Apollo Hospitals Q1 FY27: Strong growth, improving digital economics, and a busy expansion runway

Apollo Hospitals Enterprise Limited opened FY27 with a strong quarter, supported by healthy demand across hospitals, improving profitability in Apollo HealthCo, and a sharp improvement in AHLL’s diagnostics business.

On a consolidated basis for Q1 FY27, revenue rose 21% year on year to INR 7,043.5 crore. EBITDA increased 28% to INR 1,092.0 crore, and PAT grew 34% to INR 580.5 crore. Management attributed the quarter’s performance to sustained momentum across the integrated platform, including high-acuity specialties in hospitals, stronger unit economics in HealthCo, and better margin mix in diagnostics.

Hospitals lead growth as occupancy improves

Healthcare Services, the core hospital business, delivered revenue of INR 3,567.0 crore, up 22% year on year. Operating performance was strong: inpatient discharges grew 13% to 171,662 and occupancy improved to 70% from 65% last year. Average revenue per inpatient increased 8% to INR 186,630.

Management explained that hospital growth was driven by a blend of factors. Established hospitals saw 11% volume growth, 4% pricing, and 3% benefit from case mix and payer mix. High-acuity Congo-T specialties continued to be a key driver, with management stating these specialties contribute around 62% of inpatient net revenues.

Hospital profitability remained healthy. Healthcare Services EBITDA was INR 861.7 crore with a margin of 24.2%. Management highlighted that established hospitals delivered EBITDA margins of 25.9%, helped by operating leverage, case mix improvement, and productivity initiatives. Healthcare Services ROCE was reported at 28.5%.

Financial snapshot (Q1 FY27)

Note: Apollo HealthCo EBITDA is post 24/7 operating cost and ESOP charges as presented.

Expansion plan: near-term ramp, long-term capacity build

Apollo’s growth plan remains centered on adding beds and deepening its presence in key metros and Tier 1 markets. The company commissioned five new hospitals over the last two quarters and disclosed that these new units had pre-operative expenses and losses of INR 37.5 crore in Q1 FY27. In the earnings call, management quantified new hospitals’ EBITDA loss at INR 38 crore for the quarter.

The company’s expansion table indicates 380 census beds have been operationalized so far from the recently commissioned set, with the remaining 620 planned to be progressively activated over the next 12 to 18 months, aligned with ramp-up.

Gurgaon is a key near-term launch. Management said the unit will see a soft launch in September and open in October, with the CFO suggesting meaningful revenue contribution would ramp from Q4 as inpatient volumes take time to build.

Beyond FY27, Apollo shared a multi-year expansion plan through FY31. The plan targets census bed capacity increasing to about 14,100 from 9,857 in Q1 FY27. Total project cost is shown at about INR 11,152 crore, with about INR 7,500 crore yet to be spent. Management stated the expansion is expected to be funded largely from internal accruals and highlighted a comfortable debt position.

Apollo HealthCo: profitability improving as digital losses shrink

Apollo HealthCo reported Q1 FY27 revenue of INR 2,977.0 crore, up 20% year on year. Within this, offline pharmacy distribution revenue was INR 2,628.7 crore, while online pharmacy distribution plus Apollo 24/7 generated INR 348.4 crore.

HealthCo EBITDA after 24/7 operating cost and ESOP charges was INR 171.4 crore, compared with INR 93.8 crore in Q1 FY26, reflecting improved profitability. A major highlight was the reduction in digital cash loss, reported at INR 9.7 crore for Q1 FY27 excluding ESOP charges. Management stated that the digital vertical is poised to achieve breakeven in the upcoming quarter.

Operational scale remains significant. The company reported 7,440 operating pharmacy stores as of June 30, 2026 and about 49 million registered users on Apollo 24/7. Platform GMV in Q1 FY27 was INR 535 crore, up 23% year on year.

Management also discussed insurance as a growing adjacency, built as a corporate agent model that leverages Apollo’s existing customer base rather than heavy customer acquisition spending. However, leadership acknowledged setbacks in a feet-on-street distribution approach and said it is being reworked. The company guided that the insurance business could breakeven by the end of Q3.

AHLL: diagnostics drives margin improvement

Apollo Health and Lifestyle Ltd (AHLL) posted Q1 FY27 revenue of INR 499.5 crore, up 15% year on year. EBITDA rose 46% to INR 59.0 crore, taking EBITDA margin to 11.8%. PAT remained slightly negative at INR 1.1 crore loss, an improvement from the prior year’s loss.

The quarter’s improvement was driven largely by diagnostics. AHLL diagnostics revenue grew 31% year on year to INR 200.3 crore and diagnostics EBITDA increased to INR 28.1 crore, with margin rising to 14.0% from 7.8% last year.

The company’s diagnostics footprint as of June 30, 2026 included 116 labs and 2,550 plus collection centers, with presence in over 440 cities. Management also highlighted strong growth in wellness and specialty tests, with wellness at about 20% of diagnostics revenue and specialty tests supported by new test additions.

Corporate actions and strategic restructuring

Two strategic actions stand out in this quarter’s narrative.

First, Apollo HealthCo’s composite scheme of arrangement, approved by shareholders on June 24, 2026, outlines sequential steps to combine the omnichannel pharmacy distribution, Apollo 24/7 digital platform, remote telehealth division, and Keimed into a new company. The presentation indicates the new company is expected to become an Indian owned and controlled company and apply for listing. Estimated listing is indicated by Q4 FY27 post approvals.

Second, AHLL’s mother and child and fertility businesses are planned to combine with Cloudnine, subject to CCI approval. The presentation states the AHLL mother and child and fertility businesses are valued at INR 1,550 crore through a combination of cash and a 9.9% equity stake in the combined entity. AHLL leadership stated that, once regulatory clearance is received, focus will shift further toward scaling diagnostics and primary care.

Takeaways from Q1 FY27

Apollo’s Q1 FY27 performance reflects strong execution across hospitals, improving profitability trends in HealthCo, and margin recovery in AHLL diagnostics. Management commentary was clear on the near-term moving parts: ramp-up losses from new hospitals, the Gurgaon launch timeline, and the path to digital and insurance breakeven.

The longer-term story is capacity and platform integration. The disclosed bed expansion roadmap, along with the proposed HealthCo and Keimed restructuring and the mother-and-child combination, signals that FY27 is positioned as a transition year where Apollo aims to scale its integrated healthcare ecosystem while preserving profitability discipline.